Pharmacy Billing Services

Pharmacy billing bridges medical and pharmacy benefit systems with NCPDP transaction standards, 340B drug pricing compliance, buy-and-bill vs white-bagging models, drug-specific J-codes, biosimilar Q-codes, and waste documentation requirements that most billing teams struggle to manage.

AAPC Certified

HIPAA Compliant

All 50 States

Starting at 2.49%

Get Your Free Quote Call 888-701-6090

HIPAA Compliant

AAPC Certified

4.9/5 Rating

300+ Practices

J-codesDrug Billing

340BProgram

ASP+6%Medicare Drug

JWWaste Modifier

Why Pharmacy Billing Requires Specialty Expertise

Pharmacy billing encompasses medical benefit drug billing (J-codes administered in provider offices), 340B drug pricing program compliance, NCPDP pharmacy claims, and biosimilar coding. Medicare Part B drugs are reimbursed at ASP+6% (Average Sales Price plus 6%), and the JW modifier is required to document and bill for discarded drug quantities. The distinction between buy-and-bill and white-bagging models determines revenue capture.

Common Pharmacy CPT Codes

Our coders handle these pharmacy codes daily. This is not an exhaustive list.

Code

Description

J-codes

Drug Billing

340B

Program

ASP+6%

Medicare Drug

Waste Modifier

Pharmacy Billing Challenges We Solve

Common billing problems in pharmacy and how our team handles them.

Buy-and-Bill vs White-Bagging

Buy-and-bill maximizes revenue by purchasing drugs at discounted rates and billing payers at contracted rates. White-bagging eliminates drug revenue but reduces inventory risk.

340B Program Compliance

340B-eligible entities must track drug acquisition under 340B pricing separately from non-340B purchases to avoid duplicate discounts and audit findings.

Biosimilar Coding Updates

Biosimilar Q-codes change as new products enter the market. Using the reference biologic J-code instead of the biosimilar Q-code causes denials.

Drug Waste Documentation

CMS requires the JW modifier on claims for discarded single-use vial quantities. Failure to document waste properly triggers overpayment audits.

Common Pharmacy Denial Reasons

We prevent these before submission and appeal aggressively when they occur.

Buy-and-bill maximizes revenue by purchasing drugs at discounted rates and billing payers at contracted rates

340B-eligible entities must track drug acquisition under 340B pricing separately from non-340B purchases to avoid duplicate discounts and audit findings

Biosimilar Q-codes change as new products enter the market

CMS requires the JW modifier on claims for discarded single-use vial quantities

Revenue Opportunities Most Pharmacy Practices Miss

Buy-and-bill revenue optimization is the largest opportunity in pharmacy billing. Practices that purchase drugs at GPO or 340B pricing and bill payers at ASP+6% or contracted commercial rates capture the spread as revenue. For a practice administering 50 infusions per week with an average drug cost of $2,000 and an average reimbursement of $2,500, the $500-per-infusion margin generates $1,300,000 annually. Practices that switch to white-bagging lose this entire revenue stream. Drug waste billing with the JW modifier is the second missed opportunity. When a 400mg vial is used for a 300mg dose, the remaining 100mg is billable waste under the JW modifier. For high-cost biologics at $50-200 per unit, waste billing on 20 administrations per week with average waste of $150 per administration recovers $156,000 annually.

Payer-Specific Pharmacy Billing Tips

Medicare Part B reimburses provider-administered drugs at ASP+6%, updated quarterly. CMS publishes ASP pricing files that determine reimbursement for every HCPCS J-code and Q-code. Medicare requires the JW modifier for waste documentation and the JG modifier for 340B-acquired drugs (which are reimbursed at ASP minus 22.5% rather than ASP+6%). Commercial payers negotiate drug reimbursement separately, often using AWP-based (Average Wholesale Price) pricing rather than ASP. UnitedHealthcare and Anthem BCBS increasingly mandate biosimilar substitution through step-therapy protocols. Cigna's Evernorth specialty pharmacy division pushes white-bagging arrangements that eliminate provider buy-and-bill revenue. Aetna requires prior authorization for most specialty drugs with clinical criteria that must be documented before the first administration. We track each payer's drug formulary, preferred biosimilar lists, and buy-and-bill vs white-bagging policies.

Pharmacy Billing Best Practices

Practical tips from our coding team to maximize reimbursement and minimize denials.

Always append the JW modifier when billing for discarded drug quantities from single-use vials. CMS requires JW on the line item showing the discarded amount, separate from the administered dose line. Failure to use JW can trigger post-payment audits and refund demands.

For Medicare Part B drugs, verify the current ASP+6% reimbursement rate quarterly. Drug reimbursement rates change every quarter based on manufacturer-reported ASP data. Billing at outdated rates either leaves money on the table or creates overpayment risk.

When billing biosimilars, use the product-specific Q-code (e.g., Q5101 for infliximab-dyyb/Inflectra, Q5103 for infliximab-abda/Renflexis) rather than the reference biologic J-code (J1745 for Remicade). Payers increasingly mandate biosimilar substitution and deny the reference biologic code.

340B-purchased drugs must be billed with modifier JG (or TB for some payers) to identify the claim as 340B-acquired. Failing to apply the 340B modifier creates duplicate discount violations that trigger HRSA audits.

Track drug-specific HCPCS codes for each administration. Some drugs have per-10mg J-codes (e.g., J9035 bevacizumab per 10mg), meaning a 400mg dose requires billing 40 units. Incorrect unit calculation is the most common pharmacy billing error.

Get Expert Pharmacy Billing Support

Free billing assessment for your pharmacy practice. See where revenue is leaking.

98%+ clean claim rate

2.49% starting rate

Results in 30 days

Fill in your details and we'll call you back

Or call directly:888-701-6090

What We Handle for Pharmacy Practices

Medical benefit drug billing with J-codes

340B program billing and compliance tracking

NCPDP pharmacy claims processing

Biosimilar Q-code management

Buy-and-bill revenue optimization

Drug waste documentation with JW modifier

Specialty pharmacy billing coordination

Medicare Part B ASP+6% reimbursement management

Why Choose Go Medical Billing for Pharmacy

Pharmacy billing requires understanding both medical and pharmacy benefit systems. Our team manages J-code drug billing, 340B compliance tracking, and biosimilar coding updates that general billing companies cannot handle.

We serve pharmacy practices in all 50 states, starting at 2.49% of collections. Our credentialing team handles payer enrollment, and our A/R specialists recover aging claims.

Pharmacy Billing by State

We handle pharmacy billing in all 50 states. Select your state for location-specific payer details, Medicaid rules, and Medicare MAC policies.

California Texas Florida New York Pennsylvania Illinois Ohio Georgia North Carolina Michigan New Jersey Virginia Massachusetts Arizona Tennessee Maryland Indiana Missouri Wisconsin Colorado

View all 50 states

Related Resources

Medical Billing & Coding Services A/R Recovery Services Credentialing & Contracting Case Studies & Results Pricing

Frequently Asked Questions

Yes. We track 340B-acquired drugs separately, apply the correct modifiers (JG/TB), bill at the appropriate 340B reimbursement rate, and maintain audit-ready documentation to prevent duplicate discount violations.

We maintain a current biosimilar Q-code reference updated quarterly, verify payer-specific biosimilar substitution requirements, and ensure claims use the correct product-specific Q-code rather than the reference biologic J-code.

Get Expert Pharmacy Billing Support

Stop losing revenue to pharmacy coding errors and preventable denials. Call 888-701-6090 for a free billing assessment.

Schedule a Free Consultation Call 888-701-6090